首页 | 本学科首页   官方微博 | 高级检索  
     

血管内皮生长因子、单核细胞趋化蛋白1、分化抑制因子1在脑胶质瘤中的表达及与血管生成的相关性分析
引用本文:吴佩涛,丁凡,欧阳伟,王少兵. 血管内皮生长因子、单核细胞趋化蛋白1、分化抑制因子1在脑胶质瘤中的表达及与血管生成的相关性分析[J]. 中国现代医学杂志, 2022, 0(18): 90-94
作者姓名:吴佩涛  丁凡  欧阳伟  王少兵
作者单位:1.湖北省中西医结合医院 神经外科, 湖北 武汉 430000;2.武汉普仁医院 脊髓病中心, 湖北 武汉 430081
基金项目:中国金属学会冶金安全与健康分会健康卫生科研项目(No:jkws201824)
摘    要:目的 分析血管内皮生长因子(VEGF)、单核细胞趋化蛋白1(MCP-1)、分化抑制因子1(Id1)在脑胶质瘤中的表达及与血管生成的相关性。方法 选取2018年4月—2020年5月湖北省中西医结合医院脑胶质瘤患者150例作为病例组。另选取该院因脑外伤后行颅内减压术的50例非肿瘤患者(正常脑组织)作为对照组。对比两组患者血清VEGF、MCP-1、Id1水平,绘制ROC曲线分析血清VEGF、MCP-1、Id1水平预测脑胶质瘤发生的价值;比较不同级别脑胶质瘤患者血清VEGF、MCP-1、Id1水平及肿瘤微血管密度(MVD)值,Pearson法分析血清VEGF、MCP-1、Id1水平与MVD值的相关性。结果 病例组血清VEGF、Id1水平较对照组高,MCP-1水平较对照组低(P <0.05)。ROC曲线结果显示,血清VEGF、MCP-1、Id1水平及3者联合预测胶质瘤发生的AUC分别为0.873(95%CI:0.823,0.923)、0.776(95%CI:0.699,0.853)、0.898(95%CI:0.850,0.946)、0.908(95%CI:0.851,0.978)。高级别组...

关 键 词:脑胶质瘤  血管内皮生长因子  单核细胞趋化蛋白1  分化抑制因子  血管生成
收稿时间:2022-04-20

Expressions of vascular endothelial growth factor, monocyte chemotactic protein 1 and inhibitor of differentiation 1 in glioma and their correlations with angiogenesis
Pei-tao Wu,Fan Ding,Wei Ouyang,Shao-bing Wang. Expressions of vascular endothelial growth factor, monocyte chemotactic protein 1 and inhibitor of differentiation 1 in glioma and their correlations with angiogenesis[J]. China Journal of Modern Medicine, 2022, 0(18): 90-94
Authors:Pei-tao Wu  Fan Ding  Wei Ouyang  Shao-bing Wang
Affiliation:1.Department of Neurosurgery, Hubei Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Wuhan, Hubei 430000, China;2.Spinal Cord Disease Center, Wuhan Puren Hospital, Wuhan, Hubei 430081, China
Abstract:Objective To analyze the expressions of vascular endothelial growth factor (VEGF), monocyte chemotactic protein 1 (MCP-1), and inhibitor of differentiation 1 (Id1) in glioma and their correlations with angiogenesis.Methods A total of 150 glioma patients admitted to Hubei Provincial Hospital of Integrated Traditional Chinese and Western Medicine from April 2018 to May 2020 were selected as the case group, and 50 non-tumor patients (with normal brain tissues) undergoing intracranial decompression after brain trauma were selected as the control group. The serum levels of VEGF, MCP-1 and Id1 were compared between the two groups. The values of these indicators in predicting the occurrence of glioma were determined via ROC curve analysis. The serum levels of VEGF, MCP-1 and Id1 as well as the intratumoral microvessel density (MVD) were compared among patients with different degrees of glioma. The correlations between the serum levels of VEGF, MCP-1 and Id1 and the intratumoral MVD were analyzed by the Pearson method.Results The serum levels of VEGF and Id1 in the case group were higher than those in the control group (P < 0.05), while the serum level of MCP-1 was lower in the case group compared with the control group (P < 0.05). The ROC curve analysis revealed that the AUCs of serum levels of VEGF, MCP-1 and Id1 as well as their combination for predicting the occurrence of glioma were 0.873 (95% CI: 0.823, 0.923), 0.776 (95% CI: 0.699, 0.853), 0.898 (95% CI: 0.850, 0.946), and 0.908 (95% CI: 0.851, 0.978), respectively. The serum levels of VEGF and Id1 and intratumoral MVD were higher, and the serum level of MCP-1 was lower in patients with high degrees of glioma than those in patients with low degrees of glioma (P < 0.05). The Pearson correlation analysis showed that the intratumoral MVD was positively correlated with the serum levels of VEGF (r = 0.532, P = 0.000) and Id1 (r = 0.697, P = 0.000), but negatively correlated with the serum level of MCP-1 (r =-0.395, P = 0.003).Conclusions In glioma patients, serum levels of VEGF and Id1 are upregulated while the serum level of MCP-1 is down-regulated. These indicators are closely related to tumor angiogenesis and effectively predict the occurrence of glioma.
Keywords:glioma  vascular endothelial growth factor  monocyte chemotactic protein 1  inhibitor of differentiation 1  angiogenesis
点击此处可从《中国现代医学杂志》浏览原始摘要信息
点击此处可从《中国现代医学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号